NEWS
By M. William Salganik | January 23, 2008
CoGenesys Inc., a Rockville biotech spun off from Human Genome Sciences Inc. in 2006, is being sold for $400 million to Teva Pharmaceutical Industries Inc., an Israeli company that specializes in generic drugs, the companies announced yesterday. In a statement, Shlomo Yanai, Teva's president and chief executive officer, said Teva had decided it needed to grow in biopharmaceuticals, and was interested in CoGenesys for its "breadth of technologies and the depth of their team and pipeline."
NEWS
August 6, 2007
On August 4, 2007, Mary Elizabeth, of Parkville, beloved wife of Bill Burrill Sr.; loving mother of Bill Burrill Jr. and wife Nancy, Theresa Lacko and husband Michael, David Burrill and wife Renee, Laura Schuelke and husband Kevin, Suzanne Ray and husband Michael; loving grandmother of Tonya, Christina, Garrett, Dana, Stephanie, Eric, Bryan, Tyler, Evan, Emily, Sarah, David, and Megan; loving great-grandmother of Katie; dear sister of the late Madeline Abbott...
NEWS
October 7, 2002
S.H. Irish appointed executive director of Leadership Howard Stacie Hunt Irish has been appointed executive director of Leadership Howard County. She had served as director of the Howard County Regional Campaign for United Way of Central Maryland since August 2000. A recent graduate of the Class of 2002 of Leadership Howard County, Irish will succeed Shirley M. Burrill, who has been executive director of the organization since its inception 17 years ago. She was instrumental in formulating the group's mission: to strengthen and improve the community by providing knowledgeable, effective leaders for community organizations.
NEWS
July 1, 2002
Burrill leaving Leadership Howard County Shirley M. Burrill, executive director of Leadership Howard County, has announced that she will step down Oct. 31. Burrill was instrumental in formulating the organization's mission to strengthen and improve the community by providing knowledgeable, effective leaders for community organizations. The program now enrolls more than 40 students each year. Burrill was recognized as Volunteer Educator of the Year in 1991. Warfield's Daily Record named her one of Maryland's Top 100 Women in 1997, 1999 and this year.
NEWS
By Julie Bell | January 7, 2001
Think of it as the biotechnology industry's New Year's hangover. After partying through last year with a record 67 initial public offerings in the sector, a number of newly public biotechnology companies might see shares dive - or at least dip - in the first part of this year. The reason: Company insiders and many large shareholders suddenly will be freed from "lockup" periods that have prohibited them from trading their shares. The lockup expirations, which generally come six months after an initial public offering, could result in a flood of shares hitting the market.
NEWS
By William Patalon III | October 6, 2000
In another sign that the market for biotechnology stocks has revived, Gaithersburg-based Gen- Vec Inc., a developer of gene-based drugs, has filed for the second time to go public. GenVec had filed for an initial public stock offering in May 1998, only to shelve those plans when the market for biotechnology stocks soured. Company officials were not available for comment on the filing last night. However, in a news release issued late yesterday, the firm said that it had filed a registration statement with the Securities and Exchange Commission, a necessary step for companies seeking to go public.
NEWS
By Mark Guidera | January 23, 2000
If any theme will mark the biotechnology industry in the coming year, says industry expert G. Steven Burrill, it likely will be this: The big will grow larger while the small struggle on. Only this year, the struggle shouldn't be quite as exhausting. That said, the industry should also find a friendlier investor climate, predicts Burrill, chief executive officer of San Francisco-based merchant bank Burrill & Co., a major biotechnology industry investor. Already this year investors have been flocking back to the industry.
NEWS
By Mark Guidera | November 22, 1998
These are heady days for scientists at biotechnology companies as they take part in what many see as a remarkable revolution in our understanding of disease and efforts to develop treatments for scourges like cancer and spinal cord injuries.But for the executives charged with running many of these ventures, these are days of fret and worry: As their companies burn up cash, traditional sources of financing such as venture capital and the stock market have gone bone dry."It's really dismal," said Robert Curtis, chief executive officer of Baltimore-based Lion Pharmaceuticals Inc. The company was born two years ago as the nation's first biotech venture focused on commercializing discoveries at a major university, in this case the Johns Hopkins University's School of Medicine.
NEWS
November 9, 1998
Shirley M. Burrill has received the Good Scout award from the National Pike District of the Baltimore Area Council of the Boy Scouts of America. She was honored at a breakfast ceremony Friday at the Turf Valley Resort & Conference Center in Ellicott City.Recipients of the award are chosen for outstanding community service and leadership.Burrill has served as executive director of Leadership Howard County since its inception in 1985. An active Girl Scout in her youth, she has been a member of the Boy Scout National Pike District advisory committee.
NEWS
September 3, 1997
LET'S GET THIS STRAIGHT: Howard Community College trustees have appointed an acting president to lead the campus until they choose an interim president to serve until they select a permanent president.This is one step too many in the process of choosing a leader to replace Dwight A. Burrill, who served for 16 years at the west Columbia school before his retirement took effect Monday. Worse, it is a waste of time and money.There is no need to have two people serving in acting and interim capacities -- terms that are usually synonymous.